Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. März 2018 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Awareness Month

SALT LAKE CITY, March 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment...
28. Februar 2018 06:00 ET | Quelle: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first patient in APeX-S, a long-term safety trial...
22. Februar 2018 16:35 ET | Quelle: Arbutus Biopharma Corporation

Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology

Acuitas has No Further Rights to Use or Sublicense Arbutus LNP TechnologyArbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa.,...
22. Februar 2018 08:00 ET | Quelle: BioSig Technologies, Inc.

BioSig Technologies to Partner with Focus Marketing

Santa Monica, CA, Feb. 22, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
20. Februar 2018 07:05 ET | Quelle: Myriad Genetics, Inc.

NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer

SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for...
20. Februar 2018 06:30 ET | Quelle: ChromaDex Corporation

Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.

IRVINE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today...
15. Februar 2018 11:15 ET | Quelle: Myriad Genetics, Inc.

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer

SALT LAKE CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients...
14. Februar 2018 20:50 ET | Quelle: Arbutus Biopharma Corporation

Arbutus Enters Exclusivity Agreement with Roivant Sciences

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
14. Februar 2018 09:00 ET | Quelle: Terrestrial Energy Inc.

Terrestrial Energy Appoints Former United States Secretary of Energy Ernest Moniz to Its Advisory Board

OAKVILLE, Ontario, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Terrestrial Energy today announced the appointment of former U.S. Secretary of Energy Dr. Ernest Moniz to its Advisory Board. Dr. Moniz is the...
13. Februar 2018 21:36 ET | Quelle: Arbutus Biopharma Corporation

Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...

Vorherige Seite

Nächste Seite